Peptide Initiative

Peptide profile · Hormone Support

Cetrorelix

Fast-acting GnRH antagonist that stops premature ovulation during IVF cycles

Strong human trialsFDA approved for this use
Approximately 2-6 hoursHalf-life (varies by route of administration)
~85%Bioavailability (subcutaneous injection)
1431.06Molecular weight, Da

Molecular formula

C70H92ClN17O14

CAS number
100885-89-0
PubChem
25074887
Developed · 1993
Aeterna Zentaris Research Team, Aeterna Zentaris (formerly Arpida/Zentaris)

Amino acid sequence

Ac-D-2-Nal-D-4-Cl-Phe-D-3-Pal-Ser-Tyr-D-Cit-Leu-Lys-Pro-D-Ala-NH2

Ovulation ControlCetrorelix gives you and your doctor almost perfect control over when ovulation happens, which is the whole point of IVF.

9.8

Cycle FlexibilityYou can start cetrorelix mid-cycle or adjust dosing based on how your body responds, making treatment adaptable to your specific needs.

8.5

Side Effect ProfileMost women tolerate cetrorelix really well compared to older hormone treatments. Injection site redness is the main complaint, not serious symptoms.

8.0

Ratings out of 10.

0.25 – 3mg

Every documented dose level

PhaseDoseFrequency
Days 4-90.25 mgOnce every 24 hours
One dose covers at least 4 days; add 0.25 mg daily after if hCG is delayed3 mgSingle dose (one injection)
Build my protocolBuild my protocol opens your schedule and dose log to save, share and keep on your phone.

Best for planning ivf with precise ovulation timing & preventing premature egg release during controlled stimulation

Best for

  • Planning IVF with precise ovulation timing

    Cetrorelix is particularly well-suited for individuals focused on planning ivf with precise ovulation timing. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • Preventing premature egg release during controlled stimulation

    Cetrorelix is particularly well-suited for individuals focused on preventing premature egg release during controlled stimulation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • Managing polycystic ovary syndrome (PCOS) during fertility treatment

    Cetrorelix is particularly well-suited for individuals focused on managing polycystic ovary syndrome (pcos) during fertility treatment. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Consider alternatives if

Alternative approaches for hormone support supportConsult your healthcare provider for alternatives to Cetrorelix based on your specific needs and medical history
Alternative hormone-supporting peptidesKisspeptin-10GonadorelinPT-141 (Bremelanotide)
Non-peptide hormone supportClomiphene citrateAnastrozoleLifestyle modifications (sleep, exercise)

Do not use if

  • Known allergy to cetrorelix or any ingredient
  • Pregnancy (it may harm the developing baby)
  • Undiagnosed vaginal bleeding
  • Severe liver or kidney disease
  • Latex allergy (some syringes contain latex)

Use with caution if

  • You are taking other medications—discuss potential interactions with your healthcare provider
  • You have a history of liver or kidney disease
  • You are elderly or have multiple medical conditions
  • You are planning surgery in the near future—inform your surgeon about Cetrorelix use
  • You have any chronic health conditions that require regular monitoring

Not sure?

Compare Cetrorelix with similar peptides to find the best fit for your goals.

Route

Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training

Best sites

  • Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injection
  • Front of thighs—middle to upper portion of the outer leg
  • Back of upper arm—outer area (may need assistance from another person)

The Cetrorelix injection guide covers reconstitution · step-by-step technique · storage · a sample daily schedule.

13 common side effects · 2 serious

Emergency signs first, then what this page and MedlinePlus say.

Cetrorelix is an FDA-approved GnRH antagonist used exclusively in assisted reproductive technology with proven safety in short-term reproductive cycles.

Unlike GnRH agonists, cetrorelix lacks the initial testosterone flare, making it well-tolerated for ovarian stimulation. Primary side effects are mild and local—injection site reactions (erythema, bruising) occur in 10-20% of patients.

No systemic bone loss, cardiovascular complications, or serious adverse events have been reported in the reproductive context where treatment duration is limited (typically 7-10 days). The short treatment window in IVF protocols minimizes long-term safety concerns.

Hypersensitivity reactions are rare but possible.

Cetrorelix was studied through Phase 3 clinical trials specifically for IVF applications, with large multicenter randomized trials demonstrating safety and efficacy. Regulatory approval in the U.S.

and Europe was based on comprehensive Phase 2 and Phase 3 data in infertile patients undergoing controlled ovarian hyperstimulation. Long-term safety data beyond the typical 1-2 week treatment cycle is limited because the drug is not used for chronic applications.


Common side effects · experienced by some users

Injection site reactions (redness, itching, swelling)

Injection site reactions (redness, itching, swelling)

Management
Consult your healthcare provider for guidance.

Headache

Headache

Management
Consult your healthcare provider for guidance.

Nausea

Nausea

Management
Consult your healthcare provider for guidance.

Mild abdominal discomfort

Mild abdominal discomfort

Management
Consult your healthcare provider for guidance.

Dizziness

Dizziness

Management
Consult your healthcare provider for guidance.

Allergic reactions (rash, difficulty breathing)

Allergic reactions (rash, difficulty breathing)

Management
Consult your healthcare provider for guidance.

Ovarian hyperstimulation syndrome (OHSS) if used with other fertility drugs

Ovarian hyperstimulation syndrome (OHSS) if used with other fertility drugs

Management
Consult your healthcare provider for guidance.

Ovarian cysts

Ovarian cysts

Management
Consult your healthcare provider for guidance.

Vaginal bleeding

Vaginal bleeding

Management
Consult your healthcare provider for guidance.

Mood changes

Mood changes

Management
Consult your healthcare provider for guidance.

Liver enzyme changes

Liver enzyme changes

Management
Consult your healthcare provider for guidance.

Pelvic pain

Pelvic pain

Management
Consult your healthcare provider for guidance.

Severe allergic reaction

Severe allergic reaction

Management
Consult your healthcare provider for guidance.

Serious side effects

Severe allergic reaction

In rare cases, Cetrorelix may trigger a severe allergic reaction including difficulty breathing, facial swelling, or widespread rash. This requires immediate medical attention.

Management
STOP treatment immediately and seek emergency medical care. Do not restart without medical clearance. Report all allergic reactions to your healthcare provider.


Stop and seek help if

  • Severe or worsening side effects that don't improve with dose adjustment or supportive care
  • Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
  • Your healthcare provider recommends discontinuation based on your clinical response
  • Development of any new medical condition that may be contraindicated with Cetrorelix
  • Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
  • Abnormal lab results or clinical markers that suggest adverse effects

Cetrorelix should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.


With other peptides

  • SafeFollicle Stimulating Hormone (FSH) — FSH stimulates your ovaries to grow multiple follicles while cetrorelix prevents premature ovulation—they work together perfectly.
  • SafeHuman Menopausal Gonadotropin (hMG) — This combination hormone provides both FSH and LH stimulation while cetrorelix blocks the unwanted LH surge.
  • SafeProgesterone — After egg retrieval, progesterone prepares your uterus for implantation while cetrorelix has done its job preventing ovulation.

With medications

  • CautionGnRH Agonists (Lupron, Buserelin) — Both affect GnRH signaling. Using both together would be like fighting yourself—they work against each other.
  • CautionCertain hormone contraceptives — Birth control pills taken right before cetrorelix can interfere with how well the antagonist works. Your doctor will tell you when to stop birth control.

With supplements

  • SafeMultivitamins — Generally safe to take alongside Cetrorelix. Space doses apart if taking oral formulations to ensure optimal absorption.
  • SafeElectrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.

Strong human trials · first signs within 1-2 hours

Evidence level

Strong human trials

(Phase 3 or FDA approved)

100/100

Regulatory status

FDA approved for this use

Onset of effects

Moderate

(1-2 weeks)


How it works

Cetrorelix immediately blocks GnRH receptors to prevent premature ovulation during fertility treatment.

Unlike older hormone drugs that work slowly, cetrorelix stops the LH surge within hours, giving doctors exact control over egg maturation timing. This precision dramatically improves IVF success rates and reduces dangerous ovarian hyperstimulation.

The deeper mechanism

Cetrorelix is a synthetic GnRH antagonist decapeptide with N-terminal acetylation and substitutions including D-2-naphthylalanine and chloro-D-phenylalanine that provide high-affinity competitive antagonism at pituitary GnRH receptors.

Unlike GnRH agonists, cetrorelix produces immediate suppression without prior stimulation or flare, achieving LH suppression within 1-2 hours of administration.

During controlled ovarian hyperstimulation, cetrorelix prevents the spontaneous LH surge that would trigger ovulation before egg retrieval.

The peptide is given via daily subcutaneous injection during the stimulation cycle, with reversible receptor blockade that clears within 24 hours of the final dose.

This precise, immediate control enables synchronized egg maturation and retrieval, optimizing IVF success by allowing optimal timing of hCG trigger injection.


What to expect

  1. Within 1-2 hours

    What you might notice

    • Peak blood levels reached
    • The medication is absorbed quickly under the skin and spreads through your bloodstream.

    What's normal

    • Initial response to Cetrorelix is beginning at the cellular level
    • Different individuals experience Cetrorelix's onset at different rates
    • Transient systemic effects from initial Cetrorelix exposure are common

    What's next

    • Maintain consistent Cetrorelix administration as prescribed
    • Document subjective effects and physical markers daily
    • Schedule a check-in with your provider about initial observations
  2. Within 8 hours

    What you might notice

    • LH surge prevention begins
    • Your pituitary stops responding to your body's natural GnRH signals.

    What's normal

    • Cetrorelix is achieving sufficient receptor engagement
    • Initial mechanism of Cetrorelix is taking effect
    • Early transient effects from Cetrorelix administration are resolving

    What's next

    • Maintain consistent Cetrorelix administration as prescribed
    • Document subjective effects and physical markers daily
    • Schedule a check-in with your provider about initial observations
  3. 24-48 hours after last dose

    What you might notice

    • Normal hormone signaling returns
    • Once cetrorelix is out of your system, your pituitary can respond to GnRH again.

    What's normal

    • Cetrorelix is achieving sufficient receptor engagement
    • Initial mechanism of Cetrorelix is taking effect
    • Early transient effects from Cetrorelix administration are resolving

    What's next

    • Maintain consistent Cetrorelix administration as prescribed
    • Document subjective effects and physical markers daily
    • Schedule a check-in with your provider about initial observations
  4. 3-5 days into treatment

    What you might notice

    • Eggs are ready for retrieval
    • During this time, your eggs are maturing while cetrorelix prevents them from being released too early.

    What's normal

    • Cetrorelix response patterns are emerging
    • Initial Cetrorelix response is consistent with mechanism expectations
    • Early tolerance development to Cetrorelix is not expected

    What's next

    • Assess whether Cetrorelix response aligns with expectations
    • Plan next steps based on initial Cetrorelix tolerance and response
    • Establish baseline monitoring for Cetrorelix response tracking

Signs it's working

Treatment Response

  • Improvement in the primary symptoms or condition being treated
  • Positive changes in relevant lab values or clinical markers
  • Consistent, stable response to Cetrorelix over time
  • Reduction in symptom frequency or severity

Signs it's working

General Well-being

  • Improved energy levels and daily functioning
  • Better quality of life related to the treated condition
  • Manageable or absent side effects indicating good tolerance
  • Positive feedback from healthcare provider during check-ups

Not seeing results?

Common reasons

  • Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
  • Insufficient time at target dose—most compounds need several weeks to show full benefits
  • Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
  • Individual variation in response—genetics, metabolism, and other factors affect outcomes
  • Underlying conditions or medications interfering with absorption or effectiveness
  • Improper storage leading to degraded product—always verify proper storage conditions

125 registered studies, 11 still enrolling.

125registered studies
11recruiting now
59phase 3 or 4
24with published results

By phase

Phase 4

34

Phase 3

20

Phase 2

12

Phase 2/3

5

Phase 1/2

4

Early Phase 1

3

No phase

47

A trial spanning two phases is counted in both, so these can sum above the total. Observational studies carry no phase.

What kind of research

Gave the drug

117

Records only

8

About 21,563 people took part in the studies that actually administered Cetrorelix. Observational studies analyse the records of people already taking it — nobody was given anything for the study, so they are counted separately and cannot show cause and effect.


Most recent

  • NCT07732348 Not Yet Recruiting195 enrolled

    Oral GnRH Antagonist (Linzagolix) Versus Injectable GnRH Antagonist and Progestin-primed Ovarian Stimulation (PPOS) in Controlled Ovarian Stimulation for in Vitro Fertilization: a Prospective Comparative Observational Study

    Centro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita)

  • NCT07736261 Phase 1/2Not Yet Recruiting100 enrolled

    Drospirenone-Primed Ovarian Stimulation Versus GnRH Antagonist Protocol in Poor Ovarian Responders Undergoing Freeze-All IVF/ICSI

    Ahmed Saad

  • NCT05326087 Phase 3Not Yet Recruiting204 enrolled

    Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A

    ShangHai Ji Ai Genetics & IVF Institute

See all 125 trials for Cetrorelix

Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered twice is counted once. A study is counted when Cetrorelix is named as an intervention; studies that only mention it in passing are not.

How is cetrorelix different from birth control pills?

Birth control pills use hormones to prevent ovulation, but they work over weeks. Cetrorelix is a peptide antagonist that works within hours by blocking hormone receptors. It's much faster and more precise, which is why it's perfect for IVF where timing is everything.

Will cetrorelix hurt my fertility long-term?

No. Cetrorelix is temporary—it only blocks GnRH while you're using it. Once you stop injecting, your pituitary gland goes right back to normal signaling. It's like turning off a light switch, not permanent damage.

What if I accidentally skip a dose?

Take it as soon as you remember if it's the same day. If you miss a whole day and are already at risk of ovulation, call your clinic immediately. They may adjust your retrieval timing or add another dose. Don't just skip doses without asking your doctor.

Can I use cetrorelix if I'm overweight or have PCOS?

Yes, absolutely. Women with PCOS often benefit from cetrorelix because it gives better control when your ovaries tend to be extra responsive. Your doctor may adjust the dose or timing, but it's a safe choice for higher responders.

How much does cetrorelix cost?

Costs vary, but a typical IVF cycle with cetrorelix injections runs $200-800 depending on how many doses you need. Insurance sometimes covers it because it's FDA-approved for IVF. Ask your clinic about pricing and financial assistance programs.

What if I'm allergic to the injection?

True allergies to cetrorelix are rare, but if you get hives, swelling, or trouble breathing, go to the ER immediately. Minor redness at the injection site is normal and not an allergy. Talk to your doctor about any reactions.

Ready for the protocol?

Every dosing tier, administration route, timing note, and dose-adjustment rule for Cetrorelix, on one page.

Cetrorelix dosing protocol

Medical disclaimer

Cetrorelix is FDA approved for the use described here. It is a prescription medication that should only be started, adjusted, or stopped under the supervision of a qualified healthcare provider. This information is for educational purposes only and should not be construed as medical advice. Always consult with a qualified healthcare provider before starting any new supplement or treatment protocol.

Last updated: Oct 11, 2026

0.25 – 3 mg Once every 24 hours or single dose (one injection) · onset 1-2 weeks
Open the Cetrorelix calculatorCetrorelix calculator